NFKB1 and AL amyloidosis: Ixazomib is a proteasome inhibitor that binds to the 20S proteasome at β5 subunit and inhibits its activity. It reduces the release of cytokines by inhibiting the NF-κB pathway in vitro in multiple myeloma stromal cells.